Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$15.02 USD

15.02
286,804

-0.12 (-0.76%)

Updated Apr 22, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CPRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Catalyst Pharmaceuticals, Inc. [CPRX]

Reports for Purchase

Showing records 241 - 260 ( 415 total )

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 241

08/30/2017

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 242

08/30/2017

Company Report

Pages: 7

Firdapse Updates - Data 4Q17, Filing 1Q18, SPA for MuSK-MG1

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 243

08/14/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 244

08/11/2017

Company Report

Pages: 5

We Remain Bullish Ahead of LEMS Topline; Reit Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 245

08/10/2017

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 246

08/10/2017

Company Report

Pages: 8

2Q17 Recap - Firdapse on Track for 2H17 Filing

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 247

07/12/2017

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 248

06/23/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 249

05/22/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 250

05/15/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 251

05/12/2017

Company Report

Pages: 8

1Q17 Recap - Data Coming in 2H17

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 252

05/12/2017

Company Report

Pages: 5

Bullish Ahead of LEMS Phase 3 Data on Tap for 2H17

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 253

04/25/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 254

03/24/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 255

03/21/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 256

03/20/2017

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 257

03/20/2017

Company Report

Pages: 8

4Q16 Recap - Momentum Building for Active 2017

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 258

03/20/2017

Company Report

Pages: 6

The Year Ahead: A Strengthened Firdapse Value Proposition

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 259

03/17/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 260

02/21/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party